Posted on April 13, 2019 by Sitemaster
Some data presented a few weeks ago at the annual meeting of the European Association for Urology appear to have surprised not only the study’s authors, but pretty much everyone else as well. … READ MORE …
Filed under: Uncategorized | Tagged: low risk, replacement, serum, surgery, testosterone, TRT | 6 Comments »
Posted on March 21, 2019 by Sitemaster
Conventional wisdom (dating back to the 1940s) has long been that giving testosterone supplements to men who had been treated for prostate cancer is a really bad idea. … READ MORE …
Filed under: Uncategorized | Tagged: hypogonadal, replacement, serum, testosterone, TRT | 4 Comments »
Posted on December 31, 2018 by Sitemaster
For many years now, there have been subsets of specialists and patients who have argued that the “standard” serum testosterone level of 50 ng/dl, used by regulatory authorities and others as a measure indicating a castrate level of serum testosterone, is too high. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castrate, dhydrotestosterone, estosterone, level, serum | 18 Comments »
Posted on November 15, 2017 by Sitemaster
Discussions about the pros and cons of testosterone replacement therapy (TRT) in relation to (a) stimulating risk for prostate cancer in men who have not been diagnosed and (b) recurrence of prostate cancer among men who have been diagnosed and treated often aren’t entirely clear about a very key factor. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: hypogonadism, replacement, risk, serum, testosterone, TRT | 18 Comments »
Posted on December 16, 2016 by Sitemaster
For the past 40 years, the formal level of “effectiveness” of androgen deprivation therapy (ADT, also known as “hormone” therapy) for men treated for high-risk, progressive, and/or metastatic prostate cancer has been a serum testosterone level of < 50 ng/dl (equivalent to < 1.7 nmol/l). However, … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, serum, testosterone | 7 Comments »
Posted on October 31, 2016 by Sitemaster
A new report from a group of Italian researchers has suggested that circulating serum testosterone (T) levels in the blood may be a risk for upgrading and upstaging among men initially diagnosed with low-risk prostate cancer who are managed on active surveillance. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: active, risk, serum, surveillance, testosterone | 1 Comment »
Posted on March 19, 2015 by Sitemaster
Over the years there have been multiple debates about whether different types of androgen deprivation therapy (ADT) really do or don’t extend the survival of men with advanced prostate cancer of differing types and whether the degree to which ADT initially suppresses serum testosterone levels affects that survival. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, hormone, serum, testosterone | 48 Comments »